Cue Biopharma/CUE

$1.88

0.8%
-
1D1W1MYTD1YMAX

About Cue Biopharma

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells. The Company's platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body's intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its two oncology drug product candidates, CUE-101 and CUE-102, are exemplary programs from the interleukin 2 (IL-2) based CUE-100 series, and are representative of the HLA-A02 allele, which is prevalent in the United States and western European territories. CUE-101 HLA-A02 is engineered for the treatment of human papillomavirus positive, head and neck squamous cell carcinoma (HNSCC). CUE-102 HLA-A02, targeting Wilms' Tumor 1 protein, an oncofetal antigen known to be over-expressed in more than 20 different cancers.

Ticker

CUE

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Daniel Passeri

Employees

53

Headquarters

Boston, United States

Cue Biopharma Metrics

BasicAdvanced
$83M
Market cap
-
P/E ratio
-$1.07
EPS
1.99
Beta
-
Dividend rate
$83M
1.99028
$4.89
$1.30
299K
2.469
10.8
23.993
-73.69%
-117.5%
-96.35%
11.849
2.769
2.769
1,524.14%
20.99%
20.29%

What the Analysts think about Cue Biopharma

Analyst Ratings

Majority rating from 5 analysts.
Buy

Price Targets

Average projection from 5 analysts.
400% upside
High $15.00
Low $6.00
$1.88
Current price
$9.40
Average price target

Cue Biopharma Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-723.52% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$1.7M
-5.56%
Net income
-$12M
-8.21%
Profit margin
-723.52%
-2.81%

Cue Biopharma Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 11.35%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.29
-$0.24
-$0.29
-$0.25
-
Expected
-$0.31
-$0.34
-$0.28
-$0.28
-$0.29
Surprise
-4.92%
-29.93%
4.32%
-11.35%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Cue Biopharma stock?

Cue Biopharma (CUE) has a market cap of $83M as of May 22, 2024.

What is the P/E ratio for Cue Biopharma stock?

The price to earnings (P/E) ratio for Cue Biopharma (CUE) stock is 0 as of May 22, 2024.

Does Cue Biopharma stock pay dividends?

No, Cue Biopharma (CUE) stock does not pay dividends to its shareholders as of May 22, 2024.

When is the next Cue Biopharma dividend payment date?

Cue Biopharma (CUE) stock does not pay dividends to its shareholders.

What is the beta indicator for Cue Biopharma?

Cue Biopharma (CUE) has a beta rating of 1.99. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Cue Biopharma stock price target?

The target price for Cue Biopharma (CUE) stock is $9.4, which is 400% above the current price of $1.88. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Cue Biopharma stock

Buy or sell Cue Biopharma stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing